At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 136 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
KVD900 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-way Crossover Trial to Evaluate the Efficacy and Safety of Two Dose Levels of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II
In Brief
A Phase 3 clinical trial evaluating Placebo, KVD900 600 mg, and 1 other intervention for Hereditary Angioedema. Completed, enrolled 136 participants across 66 sites in 21 countries.
Detailed Summary
This study is a randomized, double-blind, placebo-controlled, phase III, three-way crossover clinical trial evaluating the efficacy and safety of KVD900, in the treatment of hereditary angioedema attacks in adolescent and adult Patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHereditary Angioedema
CountriesAustralia, Bulgaria, Canada, France, Germany, Greece, Hungary, Israel, Italy, Japan, Netherlands, New Zealand, North Macedonia, Poland, Portugal, Puerto Rico, Romania, Slovakia, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2023202420252026
Enrollment StartFeb 2022
First PostedMar 2022
Primary CompletionDec 2023
TodayJul 2026
First PostedMar 2, 2022
Enrollment StartFeb 22, 2022
Primary CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 4.3 years ago
Interventions
Placebodrug
Placebo to KVD900 Tablet
KVD900 600 mgdrug
KVD900 Tablet 600 mg (2 x 300 mg)
KVD900 300 mgdrug
KVD900 Tablet 300 mg (1 x 300 mg)